J&J Beats $258M Risperdal Verdict In Split La. High Court

Law360, New York (January 28, 2014, 8:11 PM EST) -- A split Louisiana Supreme Court on Tuesday nixed a $258 million jury award against Johnson & Johnson unit Janssen Pharmaceuticals Inc. over its marketing of the antipsychotic drug Risperdal, finding that the state failed to prove the companies defrauded Louisiana’s Medicaid program.

In a significant win for J&J, the state high court ruled 4-3 to reverse an August 2012 appeals court decision that preserved a $258 million jury verdict against Janssen secured by state Attorney General James D. “Buddy” Caldwell. The nearly decadelong dispute stems from...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.